Reposted by medright
Researchers studied 8,402 COVID-reactive T cells from 42 patients and found those with mild COVID had more CD8+ “killer” T cells, which fought the virus more effectively for up to 4 months.
The findings could help develop future COVID vaccines that offer longer-lasting protection.
medicalxpress.com
T-cell research reveals paths to better vaccines for COVID-19 and beyond
Two people infected with the same strain of COVID-19 can have vastly different experiences. One might never even sniffle, and the other might end up on a ventilator. But why?